Keio Univ.’s Corneal Endothelial Cell Substitute from iPS Cells Transplant Plan on Bullous Keratopathy Treatment OK’d

Tokyo (June 8, 2021)-, Keio university, jointly developing CLS001 with Cellusion Inc., announced the approval of first in human clinical research to transplant corneal endothelial cell substitute from iPS cells into Bullous Keratopathy patients. The research will be conducted by a team led by Prof. Shigeto Shimmura for the patients recurring Bullous Keratopathy after conventional cornea transplantation. The study will start through the approval of an expert panel discussion under the ministry of labor health and welfare Japan.

With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for all bullous keratopathy patients.

Details on Keio university press release, please see below.

https://www.keio.ac.jp/ja/press-releases/2021/6/8/28-80549/　

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/